Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated CancersVan K. Morris, Michael Frumovitz, Solly George et al.|The Oncologist|2023Cited by 29
Prognostic implications of minimal residual disease detection by second-look laparoscopy and circulating tumor DNA among patients with ovarian cancer after front-line therapyAnne Knisely, Amir A. Jazaeri, Sanghoon Lee et al.|Gynecologic Oncology|2024Cited by 1